Der Hautarzt

, Volume 59, Issue 10, pp 806–813 | Cite as

Immunmodulierende Antikörper in der Dermatoonkologie

Leitthema
First Online:

Zusammenfassung

Nachdem konventionelle Therapien nur eine begrenzte Effizienz bei soliden Tumoren, insbesondere beim Melanom, aufweisen, ist der Bedarf an alternativen Therapien groß. Aufgrund der Immunogenität des Melanoms bieten sich hier insbesondere immuntherapeutische Strategien an. Dabei kommen unter anderem therapeutische Antikörper zum Einsatz. Diese lassen sich danach unterscheiden, ob sie direkt eine Zell- oder komplementabhängige Zytotoxizität bewirken oder aber die Immunantwort modifizieren. Letzteres geschieht, indem inhibitorische Signalwege blockiert oder aktivierende Signalwege auf Immunzellen ausgelöst werden. Aktuell klinisch getestete, immunmodulierende Antikörper, d. h. agonistische gegen aktivierende Signalwege oder antagonistische gegen inhibierende Signalwege, sollen hier diskutiert werden.

Schlüsselwörter

CTLA4 PD-1 CD137 CD134 Immunzytokine 

Abkürzungen

APZ

Antigenpräsentierende Zelle

CTL

Zytotoxische T-Lymphozyten

CTLA-4

„Cytotoxic T lymphocyte antigen-4“

DZ

Dendritische Zellen

HAMA

Humane Anti-Maus-Antikörper

mAb

Monoklonaler Antikörper

Immunmodulatory antibodies in the treatment of skin cancer

Abstract

Since the efficacy of conventional therapeutic approaches is limited in patients with solid tumors, especially melanoma, there is a need for alternatives. Because of the immunogenicity of melanoma, immunotherapeutic approaches have been widely tested. Among others, therapeutic antibodies have been used. These can be distinguished by their modus operandi, e.g. induction of cellular or complement-dependent cytotoxicity against tumor cells, or modification of immune responses. The latter can be achieved by blockage of inhibitory signal pathways or stimulation of excitatory signal pathways of immune response. We discuss the immunomodulatory antibodies which are currently in clinical testing.

Keywords

CTLA-4 PD-1 CD137 CD134 Immunocytokines 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Axel Hauschild war als Investigator an Studien zu CTLA-4-Antikörpern der Firmen BMS/Medarex und Pfizer sowie als Advisory-Board-Teilnehmer für beide Firmen tätig. Jürgen Becker war als Investigator an Studien zu CTLA-4-Antikörpern der Firmen BMS/Medarex tätig; Speakers Bureau Merck Serono und MBS.

Literatur

  1. 1.
    Blank C, Kuball J, Voelkl S et al. (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119: 317–327PubMedCrossRefGoogle Scholar
  2. 2.
    Brahmer JR, Topalian S, Wollner I et al. (2008) Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol (Meeting Abstracts) 26: 3006Google Scholar
  3. 3.
    Cardoso AA, Seamon MJ, Afonso HM et al. (1997) Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90: 549–561PubMedGoogle Scholar
  4. 4.
    Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565–594PubMedCrossRefGoogle Scholar
  5. 5.
    Diehl L, den Boer AT, Schoenberger SP et al. (1999) CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5: 774–779PubMedCrossRefGoogle Scholar
  6. 6.
    Gladue RP, Cole SH, Donovan C et al. (2006) In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells and chemotherapy. J Clin Oncol (Meeting Abstracts) 24: 2514Google Scholar
  7. 7.
    Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23: 515–548PubMedCrossRefGoogle Scholar
  8. 8.
    Hodi FS, Butler M, Oble DA et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005–3010PubMedCrossRefGoogle Scholar
  9. 9.
    Hodi FS, Mihm MC, Soiffer RJ et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712–4717PubMedCrossRefGoogle Scholar
  10. 10.
    Iwai Y, Terawaki S, Honjo T (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17: 133–144PubMedCrossRefGoogle Scholar
  11. 11.
    Ju SA, Lee SC, Kwon TH et al. (2005) Immunity to melanoma mediated by 4–1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 83: 344–351PubMedCrossRefGoogle Scholar
  12. 12.
    Kaleeba JA, Offner H, Vandenbark AA et al. (1998) The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int Immunol 10: 453–461PubMedCrossRefGoogle Scholar
  13. 13.
    King DM, Albertini MR, Schalch H et al. (2004) Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22: 4463–4473PubMedCrossRefGoogle Scholar
  14. 14.
    Köhler G, Milstein C (1992) Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnol 24: 524–526Google Scholar
  15. 15.
    Llopiz D, Dotor J, Zabaleta A et al. (2008) Combined immunization with adjuvant molecules poly (I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother 57: 19–29PubMedCrossRefGoogle Scholar
  16. 16.
    O’Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614–2627CrossRefGoogle Scholar
  17. 17.
    Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18: 206–213PubMedCrossRefGoogle Scholar
  18. 18.
    Rabu C, Quemener A, Jacques Y et al. (2005) Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 280: 41472–41481PubMedCrossRefGoogle Scholar
  19. 19.
    Redmond WL, Weinberg AD (2007) Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 27: 415–436PubMedGoogle Scholar
  20. 20.
    Riley JL, June CH (2007) The road to recovery: translating PD-1 biology into clinical benefit. Trends Immunol 28: 48–50PubMedCrossRefGoogle Scholar
  21. 21.
    Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147–159PubMedCrossRefGoogle Scholar
  22. 22.
    Schwartz RS (2004) Paul Ehrlich’s magic bullets. N Engl J Med 350: 1079–1080PubMedCrossRefGoogle Scholar
  23. 23.
    Sharpe AH, Abbas AK (2006) T-cell costimulation – biology, therapeutic potential and challenges. N Engl J Med 355: 973–975PubMedCrossRefGoogle Scholar
  24. 24.
    Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239–245PubMedCrossRefGoogle Scholar
  25. 25.
    Sotomayor EM, Borrello I, Tubb E et al. (1999) Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5: 780–787PubMedCrossRefGoogle Scholar
  26. 26.
    Suntharalingam G, Perry MR, Ward S et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018–1028PubMedCrossRefGoogle Scholar
  27. 27.
    Sznol M, Hodi FS, Margolin K et al. (2008) Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody in patients (pts) with advanced cancer (CA). J Clin Oncol (Meeting Abstracts) 26: 3007Google Scholar
  28. 28.
    Tanner JE (2005) Designing antibodies for oncology. Cancer Metastasis Rev 24: 585–598PubMedCrossRefGoogle Scholar
  29. 29.
    Terheyden P, Straten P, Brocker EB et al. (2000) CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes. J Immunol 164: 6633–6639PubMedGoogle Scholar
  30. 30.
    Straten P, Guldberg P, Seremet T et al. (1998) Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA 95: 8785–8790PubMedCrossRefGoogle Scholar
  31. 31.
    Todryk SM, Tutt AL, Green MH et al. (2001) CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 248: 139–147PubMedCrossRefGoogle Scholar
  32. 32.
    Vinay DS, Cha K, Kwon BS (2006) Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 84: 726–736PubMedCrossRefGoogle Scholar
  33. 33.
    Vonderheide RH, Flaherty KT, Khalil M et al. (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25: 876–883PubMedCrossRefGoogle Scholar
  34. 34.
    Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23–68PubMedCrossRefGoogle Scholar
  35. 35.
    Wong RM, Scotland RR, Lau RL et al. (2007) Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 19: 1223–1234PubMedCrossRefGoogle Scholar
  36. 36.
    Xu D, Gu P, Pan PY et al. (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 109: 499–506PubMedCrossRefGoogle Scholar
  37. 37.
    Xu DP, Sauter BV, Huang TG et al. (2005) The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 12: 1526–1533PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Klinik für Dermatologie, Allergologie und VenerologieUniversitätshautklinik WürzburgWürzburgDeutschland
  2. 2.Klinik für Dermatologie, Allergologie und VenerologieUniversitätsklinikum KielKielDeutschland

Personalised recommendations